Global Validation Regulations & Standards

Data Integrity by Design: Applying Annex 11, Part 11 and GAMP 5 Principles

Data Integrity by Design: Applying Annex 11, Part 11 and GAMP 5 Principles Data Integrity by Design: Applying Annex 11, Part 11 and GAMP 5 Principles In the field of pharmaceuticals, the importance of data integrity cannot be overstated. Regulatory authorities like the US FDA, EMA, and MHRA have emphasized the need for robust systems that ensure data integrity by…

Continue Reading Data Integrity by Design: Applying Annex 11, Part 11 and GAMP 5 Principles

Electronic Signatures: Meeting Part 11 and Annex 11 Requirements

Electronic Signatures: Meeting Part 11 and Annex 11 Requirements The integration of electronic signatures within pharmaceutical environments is governed by stringent regulatory frameworks that aim to ensure the authenticity, integrity, and accountability of electronic records. In this article, we will explore the expectations set forth by the US FDA under 21 CFR Part 11, the EU GMP Annex 11, and…

Continue Reading Electronic Signatures: Meeting Part 11 and Annex 11 Requirements

Spreadsheet and Small Tool Validation for Annex 11/Part 11 Compliance

Spreadsheet and Small Tool Validation for Annex 11/Part 11 Compliance Spreadsheet and Small Tool Validation for Annex 11/Part 11 Compliance The pharmaceutical industry is characterized by strict regulatory requirements that ensure the quality and integrity of data generated through computerized systems. This article provides a detailed, step-by-step guide on validating spreadsheets and small tools to ensure compliance with EU GMP…

Continue Reading Spreadsheet and Small Tool Validation for Annex 11/Part 11 Compliance

Validating Cloud and SaaS GxP Systems Under Annex 11 and Part 11

Validating Cloud and SaaS GxP Systems Under Annex 11 and Part 11 As the pharmaceutical industry increasingly adopts digital technologies, understanding the regulatory framework for validating cloud-hosted Good Practice (GxP) systems becomes imperative for compliance. This article elucidates the regulatory expectations set forth by the US FDA, EMA, and other governing bodies concerning the validation of cloud environments and Software…

Continue Reading Validating Cloud and SaaS GxP Systems Under Annex 11 and Part 11

Supplier Assessment and Hosting Agreements for GxP Cloud Environments

Supplier Assessment and Hosting Agreements for GxP Cloud Environments Supplier Assessment and Hosting Agreements for GxP Cloud Environments In recent years, the pharmaceutical industry has increasingly adopted cloud-based solutions to enhance operational efficiency and flexibility. However, with these advancements come a myriad of regulatory requirements that must be adhered to, especially when dealing with Good Practice (GxP) cloud hosting environments….

Continue Reading Supplier Assessment and Hosting Agreements for GxP Cloud Environments

Periodic Review of GxP Computerised Systems: Annex 11 and Part 11 Expectations

Periodic Review of GxP Computerised Systems: Annex 11 and Part 11 Expectations Introduction to GxP Computerised Systems Validation The validation of GxP (Good Practice) computerized systems is a critical component of pharmaceutical quality assurance. It ensures that systems used in the manufacture, control, and distribution of pharmaceutical products comply with relevant regulatory requirements, including EU GMP Annex 11 and 21…

Continue Reading Periodic Review of GxP Computerised Systems: Annex 11 and Part 11 Expectations

Computer System Validation Documentation: Annex 11 and Part 11–Ready Packages

Computer System Validation Documentation: Annex 11 and Part 11–Ready Packages In the highly regulated pharmaceutical industry, the implementation and maintenance of computerized systems must comply with stringent guidelines set forth by regulatory authorities like the US FDA, EMA, and MHRA. Computer System Validation (CSV) ensures that these systems perform as intended, thereby guaranteeing data integrity, patient safety, and product quality….

Continue Reading Computer System Validation Documentation: Annex 11 and Part 11–Ready Packages

Common Annex 11/Part 11 Data Integrity Findings in FDA, EMA and MHRA Inspections

Common Annex 11/Part 11 Data Integrity Findings in FDA, EMA and MHRA Inspections Common Annex 11/Part 11 Data Integrity Findings in FDA, EMA and MHRA Inspections As pharmaceutical companies operate within the stringent guidelines set forth by regulatory agencies, understanding common data integrity findings related to Annex 11 and 21 CFR Part 11 is imperative. This article provides a comprehensive…

Continue Reading Common Annex 11/Part 11 Data Integrity Findings in FDA, EMA and MHRA Inspections

Configurable vs Custom Applications: Annex 11 and Part 11 Impact on CSV

Configurable vs Custom Applications: Annex 11 and Part 11 Impact on CSV In the realm of pharmaceutical validation, understanding the nuances between configurable and custom applications is critical for ensuring compliance with regulatory standards. This article explores the implications of these categories within the framework of Annex 11 and 21 CFR Part 11, focusing on their impact on computer system…

Continue Reading Configurable vs Custom Applications: Annex 11 and Part 11 Impact on CSV

Risk-Based Testing of GxP Systems: Applying Annex 11 and GAMP 5 Principles

Risk-Based Testing of GxP Systems: Applying Annex 11 and GAMP 5 Principles In an era where global pharmaceutical regulations are continuously evolving, risk-based validation approaches have taken a front seat, especially with the advent of Annex 11 and GAMP 5 principles governing computerized systems. This regulatory explainer manual focuses on the nuanced expectations surrounding risk-based CSV testing under the auspices…

Continue Reading Risk-Based Testing of GxP Systems: Applying Annex 11 and GAMP 5 Principles